Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma

Annals of Oncology

Volumn 16, Issue 7, 2005, Pages 1160-1168

  Hutchings, M ^a   Mikhaeel, N George ^a   Fields, P A ^a   Nunan, T ^a   Timothy, A R ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Fluorodeoxyglucose F18; Hodgkin lymphoma; Positron emission tomography; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; MELPHALAN; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ACCURACY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; CLINICAL TRIAL; MIDDLE AGED; SCINTISCANNING; SURVIVAL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 25444437438     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi200     Document Type: Article

References (31)

1. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J. Med 1998; 339: 1506-1514.
2. Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin. Oncol 1989; 7: 1630-1636.
3. Oza AM, Ganesan TS, Leahy M et al. Patterns of survival in patients with Hodgkin's disease: Long follow up in a single centre. Ann Oncol 1993; 4: 385-392.
4. Jerusalem G, Beguin Y, Fassotte MF et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 2001; 86: 266-273.
5. Weihrauch MR, Re D, Bischoff S et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2002; 81: 20-25.
6. Partridge S, Timothy A, O'Doherty MJ et al. 2-Fluorine-1.8-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution. Ann Oncol 2000; 11: 1273-1279.
7. Jerusalem G, Beguin Y, Fassotte MF et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000; 85: 613-618.
8. Mikhaeel NG, Timothy AR, O'Doherty MJ et al. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma - comparison with CT. Leuk Lymphoma 2000; 39: 543-553.
9. Spaepen K, Stroobants S, Dupont P et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13: 1356-1363.
10. Hoekstra OS, Ossenkoppele GJ, Golding R et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 1993; 34: 1706-1710.
11. Kostakoglu L, Coleman M, Leonard JP et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002; 43: 1018-1027.
12. Torizuka T, Nakamura F, Kanno T et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol. Imaging 2004; 31: 22-28.
13. Friedberg JW, Fischman A, Neuberg D et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: A blinded comparison. Leuk Lymphoma 2004; 45: 85-92.
14. Hutchings M, Eigtved AI, Specht L. FDG-PET in the clinical management of Hodgkin lymphoma. Crit Rev Oncol Hematol 2004; 52: 19-32.
15. Collett D. Modelling Survival Data in Medical Research, 2nd edition. Boca Raton, FL: Chapman & Hall-CRC 2003.
16. Landau S, Everitt BS. A Handbook of Statistical Analyses using SPSS. Boca Raton, FL: Chapman & Hall-CRC 2004.
17. Mauch PM, Armitage JO, Diehl V et al. Hodgkin's Disease. Philadelphia, PA: Lippincott-Williams & Wilkins 1999.
18. Hancock SL, Hoppe RT. Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol 1996; 6: 225-242.
19. Henry-Amar M, Somers R. Survival outcome after Hodgkin's disease: A report from the international data base on Hodgkin's disease. Semin Oncol 1990; 17: 758-768.
20. Hoppe RT. Hodgkin's disease: Complications of therapy and excess mortality. Ann Oncol 1997; 8 (Suppl 1): 115-118.
21. Specht L, Gray RG, Clarke MJ, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: A meta-analysis of 23 randomized trials involving 3888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 1998; 16: 830-843.
22. Kogel KE, Sweetenham JW. Current therapies in Hodgkin's disease. Eur J Nucl Med Mol. Imaging 2003; 30 (Suppl 1): S19-S27.
23. Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-2395.
24. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
25. Yuen AR, Rosenberg SA, Hoppe RT et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997; 89: 814-822.
26. Sweetenham JW, Carella AM, Taghipour G et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: Results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 1999; 17: 3101-3109.
27. Lohri A, Barnett M, Fairey RN et al. Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: Identification of risk factors from the British Columbia experience 1970 to 1988. Blood 1991; 77: 2292-2298.
28. Mikhaeel NG, Hutchings M, Fields PA et al. FDG-PET after 2-3 cycles of chemotherapy predicts progression-free and overall survival in high-grade Non-Hodgkin Lymphoma. Ann Oncol 2005 (in press).
29. de Wit M, Bumann D, Beyer W et al. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997; 8 (Suppl 1): 57-60.
30. Weihrauch MR, Re D, Scheidhauer K et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 2930-2934.
31. Naumann R, Vaic A, Beuthien-Baumann B et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115: 793-800.